Breast Cancer Clinical Trial

A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Summary

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
Performance Status of 0 or 1.
Adequate bone marrow, kidney, liver, and heart function.

Exclusion Criteria:

Brain metastases requiring steroids.
Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
Active bacterial, fungal or viral infection.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT01891669

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Brigham and Women's Hospital
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT01891669

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider